Ardelyx, Inc.

ARDX ·Healthcare, Drug Manufacturers - General, United States
Financial Statements › Balance Sheet
Annual Quarterly

Balance Sheet

Line Item FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018
Assets
Cash & Equivalents $68.0M $64.9M $21.5M $96.1M $72.4M $91.0M $181.1M $78.8M
Accounts Receivable $71.8M $57.7M $22.0M $7.7M $502.0K $0 — —
Inventory $123.1M $91.2M $49.5M $28.3M — — — —
Total Current Assets $382.3M $356.5M $246.1M $153.6M $133.6M $194.7M $252.1M $176.4M
Property, Plant & Equipment $2.2M $1.5M $1.0M $1.2M $2.4M $1.9M $3.4M $5.6M
Goodwill — — — — — — — —
Intangible Assets (Excl. Goodwill) — — — — — — — —
Total Assets $501.6M $435.8M $297.6M $190.1M $149.9M $201.6M $259.8M $183.3M
Liabilities
Accounts Payable $19.2M $16.0M $11.1M $10.9M $4.3M $5.6M $2.2M $1.1M
Total Current Liabilities $88.6M $77.8M $50.4M $65.6M $52.8M $28.4M $22.2M $17.7M
Long-Term Debt $202.8M $150.9M $49.8M $26.7M $32.3M $50.8M $50.0M $52.0M
Total Liabilities $334.7M $262.5M $130.8M $91.7M $67.3M $75.5M $73.1M $67.5M
Stockholders' Equity
Retained Earnings $-946.9M $-885.3M $-846.2M $-780.1M $-712.9M $-554.8M $-460.5M $-365.5M
Total Stockholders' Equity $166.9M $173.3M $166.8M $98.3M $82.6M $126.1M $186.7M $115.8M
← Newer Page 1 of 2 Older →